Aytu BioPharma to Release Fiscal 2026 Results on September 22
News related to:Aytu BioPharma, Inc · 1 min read
Aytu BioPharma, Inc., a pharmaceutical company focused on developing innovative treatments for complex central nervous system diseases, will release its fiscal 2026 full-year and fourth-quarter operational and financial results on September 22, 2026. The company will hold a conference call and webcast to discuss the results and answer questions from investors.
According to the press release, Aytu BioPharma will report its financial and operational highlights after the market close on Tuesday, September 22, 2026. The conference call is scheduled for the same day at 4:30 p.m. Eastern time. Interested parties can access the call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers, using the participant access code 504506. The webcast will be available live and archived on the company’s website.
The company's prescription products include EXXUA® (gepirone) extended-release tablets for the treatment of major depressive disorder and treatments for attention deficit-hyperactivity disorder. Aytu BioPharma is committed to delivering its medications through best-in-class patient access programs that help enable optimal patient outcomes.
Aytu BioPharma’s fiscal year 2026 results will cover the company’s performance in the areas of research and development, sales, and market share. The financial results will provide insights into the company’s revenue, earnings, and cash flow for the period. The conference call and webcast will offer an opportunity for investors to hear directly from the company’s leadership team about their strategic plans and future outlook.
The call will be led by Ryan Selhorn, Chief Financial Officer of Aytu BioPharma, who will provide a detailed analysis of the company’s financial performance. Robert Blum, from Lytham Partners, will also be present to answer any questions from the audience.
Investors and analysts will be keen to see how the company’s efforts in advancing innovative medicines for complex central nervous system diseases have translated into financial success. The results will be closely watched to gauge the company’s progress and potential for future growth in the pharmaceutical industry.